25B-NBOMe

From Wikipedia, the free encyclopedia
Jump to: navigation, search
25B-NBOMe
2C-B-NBOMe-skeletal.svg
Systematic (IUPAC) name
2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
Clinical data
Legal status
?
Identifiers
CAS number 1026511-90-9 N
ATC code ?
PubChem CID 9977044
ChemSpider 8152636 YesY
Chemical data
Formula C18H22BrNO3 
Mol. mass 380.275 g/mol
 N (what is this?)  (verify)

25B-NBOMe (NBOMe-2C-B, BOM 2-CB, Cimbi-36, New Nexus, Nova) is a derivative of the phenethylamine hallucinogen 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor.[1][2][3][4] Anecdotal reports from users[citation needed] suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250–500 µg,[citation needed] making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly. Duration of effects lasts about 12–16 hours.[citation needed]

The carbon-11 labeled version of this compound ([11C]Cimbi-36) was synthesized and validated as a radioactive tracer for positron emission tomography (PET) in Copenhagen.[5][6][7] As a 5-HT2A receptor agonist PET radioligand, [11C]Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, [11C]Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels in vivo. [11C]Cimbi-36 is now undergoing clinical trials as a PET-ligand in humans.[8]

Drug prohibition laws[edit]

Sweden[edit]

Sveriges riksdag added 25B-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25B-NBOMe 2-(4-bromo-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.[9]

United States[edit]

On November 15, 2013, the U.S. Drug Enforcement Agency placed 25B-NBOMe (along with 25I-NBOMe and 25C-NBOMe) in Schedule I of the Controlled Substances Act, making it an illicit drug.[10]

See also[edit]

References[edit]

  1. ^ Ralf Heim PhD. (2010-02-28). "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." (in German). diss.fu-berlin.de. Retrieved 2013-05-10. 
  2. ^ Maria Silva PhD. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Universität Regensburg, 2009.
  3. ^ Silva ME, Heim R, Strasser A, Elz S, Dove S (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT(2A) receptor". Journal of Computer-aided Molecular Design 25 (1): 51–66. doi:10.1007/s10822-010-9400-2. PMID 21088982. 
  4. ^ Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience 5 (3): 243–9. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.  edit
  5. ^ Hansen, M. (2011). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. PhD Thesis, University of Copenhagen.
  6. ^ Ettrup, A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. et al. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–93. doi:10.1007/s00259-010-1686-8. PMID 21174090.  edit
  7. ^ Ettrup, A.; Holm, S. R.; Hansen, M.; Wasim, M.; Santini, M. A.; Palner, M.; Madsen, J.; Svarer, C.; Kristensen, J. L.; Knudsen, G. M. (2013). "Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand \11C]Cimbi-36". Molecular Imaging and Biology 15 (4): 376–383. doi:10.1007/s11307-012-0609-4. PMID 23306971.  edit
  8. ^ "From molecule to man: The full CIMBI-36 story" (PDF). http://www.cimbi.dk. Retrieved 2014-01-10. 
  9. ^ "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika;" (PDF) (in Swedish). http://www.lakemedelsverket.se. Retrieved 2013-10-04. 
  10. ^ http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml